Antitumor activity of a transforming growth factor alpha-Pseudomonas exotoxin fusion protein (TGF-alpha-PE40).

No abstract is available for this paper.

• Publication year

  1991

• Venue

  Cancer Research

• Publication date

  1991-06-01

• Fields of study

  Biology, Medicine

• Identifiers
  PMID 2032221
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Transforming growth factor alpha-Pseudomonas exotoxin fusion protein prolongs survival of nude mice bearing tumor xenografts.

  1990cited by this paper
• Inhibition of antibody response to Pseudomonas exotoxin and an immunotoxin containing Pseudomonas exotoxin by 15-deoxyspergualin in mice.

  1990cited by this paper
• Antitumor effects of ricin A chain immunotoxins prepared from intact antibodies and Fab' fragments on solid human Hodgkin's disease tumors in mice.

  1990cited by this paper
• Anti-Tac(Fv)-PE40, a single chain antibody Pseudomonas fusion protein directed at interleukin 2 receptor bearing cells.

  1990cited by this paper
• Detection and partial characterization of receptors for [D-Trp6]-luteinizing hormone-releasing hormone and epidermal growth factor in human endometrial carcinoma.

  1990cited by this paper
• Role of transforming growth factor-alpha in human prostate cancer cell growth.

  1989cited by this paper
• A recombinant immunotoxin consisting of two antibody variable domains fused to Pseudomonas exotoxin

  1989cited by this paper
• Characterization of epidermal growth factor receptor in primary human non-small cell lung cancer.

  1989cited by this paper
• Cytotoxic activities of a fusion protein comprised of TGFα and Pseudomonas exotoxin

  1989cited by this paper
• Antitumor activity in mice of an immunotoxin made with anti-transferrin receptor and a recombinant form of Pseudomonas exotoxin.

  1989cited by this paper
• Cytotoxicity against human tumor cells mediated by the conjugate of anti-epidermal growth factor receptor monoclonal antibody to recombinant ricin A chain.

  1989cited by this paper
• Toxoid of Pseudomonas aeruginosa exotoxin A generated by deletion of an active-site residue

  1988cited by this paper
• Epidermal growth factor in the normal and neoplastic kidney and bladder.

  1988cited by this paper
• Activity of immunotoxins constructed with modified Pseudomonas exotoxin A lacking the cell recognition domain.

  1988cited by this paper
• Expression of an altered epidermal growth factor receptor by human glioblastoma cells.

  1988cited by this paper
• Cytotoxic activity of an interleukin 2-Pseudomonas exotoxin chimeric protein produced in Escherichia coli.

  1988cited by this paper
• Selective killing of HIV-infected cells by recombinant human CD4-Pseudomonas exotoxin hybrid protein

  1988cited by this paper
• Activity of a recombinant fusion protein between transforming growth factor type alpha and Pseudomonas toxin.

  1987cited by this paper
• Redesigning nature's poisons to create anti-tumor reagents.

  1987cited by this paper
• Antitumor activity of intraperitoneal immunotoxins in a nude mouse model of human malignant mesothelioma.

  1987cited by this paper
• Antitumor effects of an immunotoxin made with Pseudomonas exotoxin in a nude mouse model of human ovarian cancer.

  1986cited by this paper
• Immunotoxins.

  1986cited by this paper
• Antibody formation against the cytotoxic proteins abrin and ricin in humans and mice

  1983cited by this paper

• Engineering growth factor ligands and receptors for therapeutic innovation.

  2024cites this paper
• Advances on Delivery of Cytotoxic Enzymes as Anticancer Agents

  2022cites this paper
• A bispecific enediyne-energized fusion protein targeting both epidermal growth factor receptor and insulin-like growth factor 1 receptor showing enhanced antitumor efficacy against non-small cell lung cancer

  2017cites this paper
• Immunotoxin Therapies for the Treatment of Epidermal Growth Factor Receptor-Dependent Cancers

  2016cites this paper
• Pseudomonas Exotoxin A‐Based Immunotoxins for Targeted Cancer Therapy

  2010cites this paper
• Affitoxin—A Novel Recombinant, HER2-specific, Anticancer Agent for Targeted Therapy of HER2-positive Tumors

  2009cites this paper
• Pseudomonas exotoxin A: from virulence factor to anti-cancer agent.

  2009cites this paper
• Enhancement of Cell Type Specificity by Quantitative Modulation of a Chimeric Ligand*

  2008cites this paper
• Transforming Growth Factor-c Pseudomonas Exotoxin Fusion Protein ( TGF-aPE 38 ) Treatment of Subcutaneous and Intraeranial Human Glioma and Medulloblastoma Xenografts in Athymie Mice

  2007influential citation
• Anti-CD3 × Anti-Epidermal Growth Factor Receptor (EGFR) Bispecific Antibody Redirects T-Cell Cytolytic Activity to EGFR-Positive Cancers In vitro and in an Animal Model

  2006cites this paper
• Immunotoxins for targeted cancer therapy

  2006cites this paper
• Papillomaviruses as targets for cancer gene therapy

  2006cites this paper
• Anti-CD 3 Anti-Epidermal Growth Factor Receptor ( EGFR ) Bispecific Antibody Redirects T-Cell Cytolytic Activity to EGFR-Positive Cancers In vitro and in an AnimalModel

  2005cites this paper
• Inhibition of signaling from Type 1 receptor tyrosine kinases via intracellular expression of single-chain antibodies

  2005cites this paper
• Cytotoxic effect of a fusion protein from transforming growth factora andPseudomonas exotoxin on rat and human bladder carcinoma cells in vitro

  2005cites this paper
• Growth factors as mediators of androgen action during the development of the male urogenital tract

  2004cites this paper
• Ligands du recepteur du facteur de croissance epidermique (r-egf), et procedes d'utilisation

  2003cites this paper
• Replacement of N‐terminal portions of TGF‐α with corresponding heregulin sequences affects ligand‐induced receptor signaling and intoxication of tumor cells by chimeric growth‐factor toxins

  2002cites this paper
• Site-specific chemical modification with polyethylene glycol of recombinant immunotoxin anti-Tac(Fv)-PE38 (LMB-2) improves antitumor activity and reduces animal toxicity and immunogenicity.

  2000cites this paper
• Targeted toxins

  1999cites this paper
• Targeted Gene Transfer System Using a Streptavidin-Transforming Growth Factor-alpha Chimeric Protein

  1999cites this paper
• Post-translational modifications of eukaryotic initiation factor-5A (eIF-5A) as a new target for anti-cancer therapy.

  1999cites this paper
• Advances in Nutrition and Cancer 2

  1999cites this paper
• Recombinant toxins in haematologic malignancies and solid tumours.

  1998cites this paper
• Recombinant heregulin-Pseudomonas exotoxin fusion proteins: interactions with the heregulin receptors and antitumor activity in vivo.

  1998cites this paper
• Anti-growth factor therapy for lung cancer.

  1998cites this paper
• Immunotoxins for targeted cancer therapy.

  1998cites this paper
• Clinical trials with Pseudomonas exotoxin immunotoxins.

  1998cites this paper
• Targeted delivery of peptides, proteins, and genes by receptor-mediated endocytosis.

  1997cites this paper
• Construction and functional characterization of scFv(14E1)-ETA - a novel, highly potent antibody-toxin specific for the EGF receptor.

  1997cites this paper
• Recombinant Fusion Toxins Targeted to Members of the ErbB Family of Receptor Tyrosine Kinases

  1997cites this paper
• Interferon alpha2 recombinant and epidermal growth factor modulate proliferation and hypusine synthesis in human epidermoid cancer KB cells.

  1997cites this paper
• Cytolytic and cytostatic properties of an anti-human Fc gammaRI (CD64) x epidermal growth factor bispecific fusion protein.

  1997cites this paper
• [Recombinant immunotoxins and chimeric toxins for targeted therapy in oncology].

  1997cites this paper
• Intra‐tumoral application of a heregulin‐exotoxin‐A fusion protein causes rapid tumor regression without adverse systemic or local effects

  1997cites this paper
• Tgfα: A member of the EGF receptor ligand family

  1996cites this paper
• Targeting the epidermal growth factor receptor for therapy of carcinomas.

  1996cites this paper
• Targeted inhibition of tumour cell growth by a bispecific single-chain toxin containing an antibody domain and TGF alpha.

  1996cites this paper
• Why toxins!

  1996cites this paper
• Cytotoxic Effects of TGF‐α‐Pseudomonas Exotoxin A Fusion Protein in Human Pancreatic Carcinoma Cells

  1996cites this paper
• Intervention in receptor tyrosine kinase-mediated pathways: recombinant antibody fusion proteins targeted to ErbB2.

  1996cites this paper
• Recombinant immunotoxins for the treatment of cancer

  1996cites this paper
• Multi-Drug Delivery System Using Streptavidin-Transforming Growth Factor-α Chimeric Protein

  1996cites this paper
• Cytotoxicity of TGF alpha-PE40 and correlation to expression of epidermal growth factor receptor.

  1995cites this paper
• Transforming growth factor alpha: expression, regulation, and biological activities.

  1995cites this paper
• Immunotoxins that target an oncogenic mutant epidermal growth factor receptor expressed in human tumors.

  1995cites this paper
• Administration of disulfide‐stabilized Fv‐immunotoxins B1(dsFv)‐PE38 and B3(dsFv)‐PE38 by continuous infusion increases their efficacy in curing large tumor xenografts in nude mice

  1995cites this paper
• EGF receptor and p185erbB‐2‐specific single‐chain antibody toxins differ in their cell‐killing activity on tumor cells expressing both receptor proteins

  1995cites this paper
• Phase I clinical study of the recombinant oncotoxin TP40 in superficial bladder cancer.

  1995cites this paper
• Inhibition of cell signalling pathways.

  1995cites this paper
• [Molecular therapeutic control and gene therapy approaches].

  1995cites this paper
• Identification of Residues That Stabilize the Single-chain Fv of Monoclonal Antibodies B3 (*)

  1995cites this paper
• The effect of epidermal growth factor receptor (EGFR) expression on in vivo growth of rat C6 glioma cells.

  1995cites this paper
• Cytotoxicity of TGFα-PE40 and correlation to expression of epidermal growth factor receptor

  1995cites this paper
• Characterization of B1(Fv)PE38 and B1(dsFv)PE38: single-chain and disulfide-stabilized Fv immunotoxins with increased activity that cause complete remissions of established human carcinoma xenografts in nude mice.

  1995cites this paper
• Role of Mesenchymal-Epithelial Interactions in Normal and Abnormal Development of Male Urogenital Glands

  1994cites this paper
• Small chimeric toxins containing only transforming growth factor alpha and domain III of Pseudomonas exotoxin with good antitumor activity in mice.

  1994cites this paper
• Interleukin‐4 receptors expressed on tumor cells may serve as a target for anticancer therapy using chimeric Pseudomonas exotoxin

  1994cites this paper
• Analysis of sequences required for the cytotoxic action of a chimeric toxin composed of Pseudomonas exotoxin and transforming growth factor alpha.

  1994cites this paper
• Immunotoxins against cancer.

  1994cites this paper
• A chimeric protein comprised of IL-4 and Pseudomonas exotoxin is cytotoxic for activated human lymphocytes.

  1994cites this paper
• In vivo activities of acidic fibroblast growth factor-Pseudomonas exotoxin fusion proteins.

  1994cites this paper
• Urinary bladder cancer: mechanisms of development and progression.

  1994cites this paper
• Targeted toxins as anticancer agents

  1994cites this paper
• Epidermal growth factor receptors in human breast carcinoma cells: a potential selective target for transforming growth factor alpha-Pseudomonas exotoxin 40 fusion protein.

  1994cites this paper
• Transforming Growth Factor-α—Pseudomonas Exotoxin Fusion Protein (TGF-α-PE38) Treatment of Subcutaneous and Intracranial Human Glioma and Medulloblastoma Xenografts in Athymic Mice

  1994cites this paper
• Gene therapy--its potential in the management of oral cancer.

  1994cites this paper
• Pharmacological modulation of peptide growth factor receptor expression on tumor cells as a basis for cancer therapy.

  1994cites this paper
• Interleukin 6 receptor mRNA in prostate carcinomas and benign prostate hyperplasia.

  1994cites this paper
• TGFα-PE40 inhibits non-small cell lung cancer growth

  1994cites this paper
• TGF alpha-PE40 inhibits non-small cell lung cancer growth.

  1994cites this paper
• A recombinant form of Pseudomonas exotoxin A containing transforming growth factor alpha near its carboxyl terminus for the treatment of bladder cancer.

  1993cites this paper
• Pseudomonas exotoxin conjugated to monoclonal antibody MRK16 specifically kills multidrug resistant cells in cultured renal carcinomas and in MDR-transgenic mice.

  1993cites this paper
• Polyethylene glycol-modified chimeric toxin composed of transforming growth factor alpha and Pseudomonas exotoxin.

  1993cites this paper
• Heparin-binding transforming growth factor alpha-Pseudomonas exotoxin A. A heparan sulfate-modulated recombinant toxin cytotoxic to cancer cells and proliferating smooth muscle cells.

  1993cites this paper
• Pseudomonas Exotoxin and Recombinant Immunotoxins Derived from It

  1993cites this paper
• Immunotoxins made with a recombinant form of Pseudomonas exotoxin A that do not require proteolysis for activity.

  1993cites this paper
• Characterization of a saporin mitotoxin specifically cytotoxic to cells bearing the granulocyte-macrophage colony-stimulating factor receptor.

  1993cites this paper
• Growth of an androgen‐sensitive human prostate cancer cell line, LNCaP, in nude mice

  1993cites this paper
• Prevention of smooth muscle cell outgrowth from human atherosclerotic plaque by a recombinant cytotoxin specific for the epidermal growth factor receptor.

  1993cites this paper
• Recombinant fusion toxins--a new class of targeted biologic therapeutics.

  1993cites this paper
• Pseudomonas exotoxin: recombinant conjugates as therapeutic agents.

  1992cites this paper
• Rational design of a chimeric toxin: an intramolecular location for the insertion of transforming growth factor alpha within Pseudomonas exotoxin as a targeting ligand.

  1992cites this paper
• Targeting growth factor receptors with fusion toxins.

  1992cites this paper
• Recombinant toxins as novel therapeutic agents.

  1992cites this paper
• Properties of chimeric toxins with two recognition domains: interleukin 6 and transforming growth factor alpha at different locations in Pseudomonas exotoxin.

  1992cites this paper
• Pharmaceutical applications

  1992cites this paper
• Cancer immunotherapy: are the results discouraging? Can they be improved?

  1992cites this paper
• Diminution of antibodies directed against tumor cell surface epitopes: a single chain Fv fusion molecule specifically recognizes the extracellular domain of the c-erbB-2 receptor.

  1992cites this paper
• Cytotoxic properties of DAB486EGF and DAB389EGF, epidermal growth factor (EGF) receptor-targeted fusion toxins.

  1991cites this paper